BCBS Kansas – Germline Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers

Effective 02-22-2022

Updated Policy Section:

• Removed section A9 “Personal history of cancer and to aid in systemic therapy decision-making for PARP-inhibitors for human epidermal receptor 2 (HER2)-negative metastatic and HER2-negative early stage, high-risk breast cancer (see Policy Guidelines)” 

Updated Policy Guidelines:

• Added new Section A:“Genetic testing for BRCA1 and BRCA2 variants in breast cancer-affected individuals who are considering systemic therapy is addressed separately in BCBSKS medical policy Germline and Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment and Immunotherapy in Breast Cancer” 
• Removed Section D: “Breast Cancer Risk Groups” 

Updated Coding Section:

• Added ICD 10 codes: D07.30-D07.39 and C79.89

Source: https://www.bcbsks.com/medical-policies/germline-genetic-testing-brca1-or-brca2-hereditary-breastovarian-cancer-syndrome-2022-02-22